The guidelines focus on three key clinical statements.
The American Academy of Dermatology has issued new recommendations regarding potentially unnecessary dermatologic tests and treatments as part of the Choosing Wisely campaign.
Amneal's triamcinolone acetonide is currently the only AP-rated generic equivalent injectable suspension available.
The patient presented to the emergency department 12 hours after choking while taking her iron supplement.
Ranolazine, an antianginal drug, has been added as a new contraindication. The labeling states that concomitant use has potential for serious and/or life-threatening reactions.
The Food and Drug Administration (FDA) has approved supplemental Biologics License Applications (sBLA) for Amgen's Prolia (denosumab) and Xgeva (denosumab).
Under drug interactions, new clinical comments regarding concomitant systemic/inhaled/nasal/ophthalmic corticosteroids have been added.
Drugs in the Pipeline
Santarus announced results from its CORE I clinical study, one of two of the company's pivotal Phase 3 clinical studies with Uceris (budesonide) in ulcerative colitis.
ACR/ARHP Annual Meeting 2013
Regarding knee osteoarthritis pain, intra-articular (IA) treatments were more efficacious than oral treatments possibly because of the integrated IA placebo effect, reported study authors at the 2013 ACR/ARHP Annual Meeting.